Anti-CSF1R therapy may not be sufficient to deplete all tumor-promoting SPP1+ macrophages, which may contribute to the poor efficacy of anti-CSF1R monotherapy in the Renca mouse tumor model and human cancer patients.15 This evidence concerns the gene CSF1R and cancer.